Thousand Oaks Biopharmaceuticals has secured 1.5 billion yuan ($236.1 million) in a new funding round led by Chinese investors as the contract development & manufacturing organisation (CDMO) looks to develop new technologies and expand operations.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
